Anson Funds Management’s Atossa Therapeutics ATOS Stock Holding History

Anson Funds Management’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-7,265	Closed	-$240K	–	16
2018 Q2	$240K	Buy	+7,265	New	+$390K	0.14%	21
2016 Q1	–	Sell	-118	Closed	-$102K	–	66
2015 Q4	$102K	Buy	+118	New	+$181K	0.03%	84

Other funds holding ATOS

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Anson Funds Management's ATOS Position: Q3 2018 in Review

Anson Funds Management sold out of Atossa Therapeutics (ATOS) in Q3 2018, closing a stake of 7,265 shares — an estimated $240K sold.

Anson Funds Management first reported a position in ATOS in Q4 2015 and held it in 2 quarters. The position peaked at $240K in Q2 2018. 16 funds tracked by Wall St. Rank hold ATOS as of Q3 2018.

Anson Funds Management reported no remaining Atossa Therapeutics position as of Q3 2018 after selling out during the quarter.
Anson Funds Management sold 7,265 Atossa Therapeutics shares in Q3 2018, an estimated $240K.
Anson Funds Management first reported a position in Atossa Therapeutics in Q4 2015 and held it in 2 quarters.
Anson Funds Management's Atossa Therapeutics position peaked at $240K in Q2 2018.
16 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2018.

Based on Anson Funds Management's 13F filing for Q3 2018, filed 14 Nov 2018.